

PE anti-mouse CD16/32 Antibody

Catalog# / Size	101307 / 50 µg 101308 / 200 µg
Clone	93
Regulatory Status	RUO
Other Names	Fcγ R III/II, Ly-17
Isotype	Rat IgG2a, λ
Description	CD16 is low affinity IgG Fc receptor III (FcR III) and CD32 is FcR II. CD16/CD32 are expressed on B cells, monocytes/macrophages, NK cells, granulocytes, mast cells, and dendritic cells. The Fc receptors bind antibody-antigen immune complexes and mediate adaptive immune responses.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	Sorted pre-B cells
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes	Clone 93 can be used for blocking of CD16/CD32 interactions with the Fc domain of immunoglobulins, but is not the same clone as 2.4G2. The 93 mAb is specific to the common epitope of CD16/CD32. Additional reported applications (for the relevant formats) include: immunoprecipitation ¹ and blocking of Fc-mediated reactions in functional studies ^{2,4,23} . It is useful for blocking non-specific binding of immunoglobulin to Fc receptors. For blocking of Fc receptors in flow cytometric analysis, pre-incubate the cells with purified anti-CD16/CD32 antibody (=1.0 µg per 10 ⁶ cells in 100 µL volume) for 5-10 minutes on ice prior to immunostaining. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 101330) (Endotoxin <0.01 EU/µg, Azide-Free, 0.2 µm filtered).
Application References	<ol style="list-style-type: none"> 1. Personal communication (IP) 2. Oliver AM, <i>et al.</i> 1999. <i>Hybridoma</i> 18:113. (Block) 3. Brummel R and Lenert P. 2005. <i>J. Immunol.</i> 174:2429. 4. Terrazas LI, <i>et al.</i> 2005. <i>Int. J. Parasitol.</i> 35:1349. (Block) 5. Clements JL, <i>et al.</i> 2006. <i>J. Immunol.</i> 177:905. 6. Mohamed W, <i>et al.</i> 2010. <i>Infect Immun.</i> 78:3306. PubMed 7. Ouchi T, <i>et al.</i> 2011. <i>J. Exp Med.</i> 208:2607. PubMed 8. Kmiecik M, <i>et al.</i> 2011. <i>J. Vis. Exp.</i> 47:2381. PubMed
(PubMed link indicates BioLegend citation)	

9. Yamazaki S, *et al.* 2012. *PLoS One*. 7:e51665. [PubMed](#)
10. Li J, *et al.* 2012. *Arthritis Rheum*. 64:1098. [PubMed](#)
11. Azuma M, *et al.* 2012. *Oncoimmunology*. 1:581. [PubMed](#)
12. Koon HW, *et al.* 2013. *J. Vis. Exp.* 68:4208. [PubMed](#)
13. Hegde VL, *et al.* 2013. *J Biol Chem*. 288:36810. [PubMed](#)
14. Huang J, *et al.* 2013. *J. Immunol Methods*. 387:254. [PubMed](#)
15. Dutow P, *et al.* 2014. *J Infect Dis*. [PubMed](#)
16. Fan Y, *et al.* 2014. *J Exp Med*. 211:313. [PubMed](#)
17. Huang HN, *et al.* 2014. *Antimicrob Agents Chemother*. 58:1538. [PubMed](#)
18. Takei S, *et al.* 2014. *Vaccine*. 32:3066. [PubMed](#)
19. Richardson ML, *et al.* 2014. *PLoS Negl Trop Dis*. 8:2825. [PubMed](#)
20. Cekanaviciute E, *et al.* 2014. *J Immunol*. 193:139. [PubMed](#)
21. Kimura T, *et al.* 2014. *Int Immunol*. 26:697. [PubMed](#)
22. Everad A, *et al.* 2014. *Nat Commun*. 5:5648. [PubMed](#)
23. Cenci E, *et al.* 2006. *J. Leuko. Biol*. 79(1):40-5. (Block)

Product Citations

1. Davis FM, *et al.* 2020. *J Immunol*. 2503:204. [PubMed](#)
2. Domingues AF, *et al.* 2020. *Elife*. 9:e51754. [PubMed](#)
3. Li DY, *et al.* 2018. *Sci Rep*. 8:17979. [PubMed](#)
4. Tripathi H, *et al.* 2020. *J Mol Cell Cardiol*. 149:95. [PubMed](#)
5. Hanhai Z, *et al.* 2021. *Aging (Albany NY)*. 13:13108. [PubMed](#)
6. Chen L, *et al.* 2022. *J Nanobiotechnology*. 20:210. [PubMed](#)
7. Xiao S, *et al.* 2008. *J Immunol*. 180:914. [PubMed](#)
8. Sun Y *et al.* 2018. *Cancer cell*. 34(4):643-658. [PubMed](#)
9. Yamamoto R *et al.* 2018. *Cell stem cell*. 22(4):600-607. [PubMed](#)
10. Swidergall M, *et al.* 2019. *Cell Rep*. 28:423. [PubMed](#)
11. Davis FM, *et al.* 2019. *Arterioscler Thromb Vasc Biol*. 39:2353. [PubMed](#)
12. Papafragkos I, *et al.* 2022. *Front Immunol*. 13:889075. [PubMed](#)
13. He C, *et al.* 2021. *Oncoimmunology*. 1897295:10. [PubMed](#)
14. Xu X, *et al.* 2021. *J Nanobiotechnology*. 19:376. [PubMed](#)
15. Paiva RS, *et al.* 2021. *Eur J Immunol*. 51:1968. [PubMed](#)
16. Jassinskaja M, *et al.* 2021. *Cell Reports*. 34(12):108894. [PubMed](#)
17. Yang SH, *et al.* 2017. *Front Immunol*. 8:1192. [PubMed](#)
18. Chen X *et al.* 2017. *Cell stem cell*. 21(6):747-760. [PubMed](#)
19. Mooney C, *et al.* 2017. *International Journal of Molecular Sciences*. 10.3390/ijms18051037. [PubMed](#)
20. Amo-Aparicio J, *et al.* 2021. *Theranostics*. 11:9805. [PubMed](#)
21. Omori S, *et al.* 2021. *Cell Reports*. 34(6):108734. [PubMed](#)
22. Dong S, *et al.* 2021. *Nature*. 591:117. [PubMed](#)
23. Martinez-Muriana A, *et al.* 2016. *Sci Rep*. 6: 25663. [PubMed](#)
24. Zaro BW, *et al.* 2020. *eLife*. 9:00. [PubMed](#)
25. Murakami K, *et al.* 2021. *Cell Reports*. 34(1):108579. [PubMed](#)
26. Kubota S, *et al.* 2019. *Nat Commun*. 10:1653. [PubMed](#)
27. Koelwyn GJ, *et al.* 2020. *Nat Med*. 1452:26. [PubMed](#)
28. Yokomizo-Nakano T, *et al.* 2020. *Cancer Res*. 80:2523. [PubMed](#)
29. van der Poel CE, *et al.* 2019. *Cell Rep*. 29:2745. [PubMed](#)
30. Golan K *et al.* 2018. *Cell stem cell*. 23(4):572-585. [PubMed](#)
31. Zegarra-Ruiz DF *et al.* 2018. *Cell host & microbe*. 25(1):113-127. [PubMed](#)
32. Kojima K, *et al.* 2011. *Am J Respir Crit Care Med*. 184:328. [PubMed](#)
33. Rai S, *et al.* 2022. *Nat Commun*. 13:5346. [PubMed](#)
34. Riedel SS, *et al.* 2021. *Molecular Cell*. 81(11):2332-2348.e9. [PubMed](#)
35. Rosnagl S, *et al.* 2016. *PLoS Biol*. 14: 1002562. [PubMed](#)
36. Baptista M, *et al.* 2016. *Nat Commun*. 7:12175. [PubMed](#)
37. Nakagawa MM, *et al.* 2018. *Cell Rep*. 25:2094. [PubMed](#)
38. Li J, *et al.* 2013. *J Immunol*. 190:597. [PubMed](#)
39. Wünsche P *et al.* 2018. *Cell stem cell*. 23(1):132-146. [PubMed](#)
40. Giotopoulos G, *et al.* 2015. *J Exp Med*. 212: 1551-1569. [PubMed](#)
41. Hohsfield LA, *et al.* 2021. *Elife*. 10:.. [PubMed](#)

RRID AB_312806 (BioLegend Cat. No. 101307)
 AB_312807 (BioLegend Cat. No. 101308)

Antigen Details

Structure	Ig superfamily, 40-60 kD
Distribution	B cells, monocyte/macrophages, NK cells, neutrophils, mast cells, dendritic cells
Function	Low affinity receptors for IgG
Ligand/Receptor	IgG
Cell Type	B cells, Dendritic cells, Macrophages, Mast cells, Monocytes, Neutrophils, NK cells
Biology Area	Immunology, Innate Immunity

Molecular Family CD Molecules, Fc Receptors

Antigen References

1. Barclay AN, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Unkeless JC. 1989. *J. Clin. Invest.* 83:355.
3. Qiu WQ, *et al.* 1990. *Science* 248:732.

Gene ID [14130](#)
[14131](#)


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

Biotin anti-mouse CD16/32, FITC anti-mouse CD16/32, PE anti-mouse CD16/32, Purified anti-mouse CD16/32, Ultra-LEAF™ Purified anti-mouse CD16/32, Alexa Fluor® 647 anti-mouse CD16/32, PE/Cyanine7 anti-mouse CD16/32, TruStain FcX™ (anti-mouse CD16/32), PerCP/Cyanine5.5 anti-mouse CD16/32, APC anti-mouse CD16/32, APC/Cyanine7 anti-mouse CD16/32, Brilliant Violet 421™ anti-mouse CD16/32, Brilliant Violet 510™ anti-mouse CD16/32, Purified anti-mouse CD16/32 (Maxpar® Ready), Brilliant Violet 711™ anti-mouse CD16/32, TotalSeq™-A0109 anti-mouse CD16/32, TotalSeq™-B0109 anti-mouse CD16/32, TotalSeq™-C0109 anti-mouse CD16/32

Product Data



C57BL/6 mouse splenocytes stained with 93 PE

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587